| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $5.8M | — | +23.0% |
| SG&A Expense | $3.4M | — | +8.8% |
| Operating Income | -$9.2M | — | -17.3% |
| Net Income | -$8.9M | — | -19.2% |
| EPS (Basic) | -$0.20 | — | +4.8% |
| EPS (Diluted) | -$0.20 | — | +4.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $9.3M | +73.9% | -42.8% |
| Short-term Investments | $16.9M | — | -10.6% |
| Current Assets | $26.8M | +76.8% | -25.6% |
| Total Assets | $32.4M | +70.1% | -17.0% |
| Current Liabilities | $7.3M | +16.8% | -5.4% |
| Total Liabilities | $9.5M | +26.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$6.1M | — | -11.5% |
| Capital Expenditures | $921K | — | +2970.0% |
| Investing Cash Flow | -$8.5M | — | -343.3% |
| Financing Cash Flow | $18.5M | — | +93.8% |
| Free Cash Flow | -$7.0M | — | -27.7% |
| +3.4% |
| Stockholders' Equity | $22.9M | +98.6% | -23.2% |